Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.37 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30940563 | 0.82 | TRPA1 (0.50) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL1033059 | 0.82 | TRPA1 (0.50) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL739760 | 0.81 | PNMT (0.49) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL1766127 | 0.81 | PNMT (0.49) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL1612050 | 0.81 | PNMT (0.49) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL8910186 | 0.80 | CYP1A2 (0.39) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL524602 | 0.79 | PNMT (0.63) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL30103334 | 0.79 | PNMT (0.63) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL2120189 | 0.77 | MAOA (0.47) | NPC1RAB9AHTR2BMAOABCHE | |
| SCHEMBL28405842 | 0.77 | PNMT (0.49) | PNMTNPC1RAB9AHTR7HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115461056-B | Inhibitors of Lebaba-specific tyrosine phosphatase (LYP) | 普渡研究基金会 | 2024-04-16 | — | — | CN | claimed |
| US-8129087-B2 | Block copolymer and substrate processing method | CANON KABUSHIKI KAISHA (JP) | 2012-03-06 | — | — | US | claimed |
| US-8080522-B2 | Polyethlene glycol modifications of thymosin alpha-1 | Institute of Pharmacology and Toxicology Academy of Military Mecical Sciences, P.L.A., China (CN) | 2011-12-20 | — | — | US | claimed |
| US-20100234396-A1 | Tetrhydropyridoindole Derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-16 | — | — | US | claimed |
| US-20090311637-A1 | BLOCK COPOLYMER AND SUBSTRATE PROCESSING METHOD | CANON KABUSHIKI KAISHA (JP) | 2009-12-17 | — | — | US | claimed |
| US-20090221487-A1 | POLYETHLENE GLYCOL MODIFICATIONS OF THYMOSIN ALPHA-1 | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2009-09-03 | — | — | US | claimed |
| EP-1725553-B1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-07 | — | — | EP | claimed |
| US-7265146-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2007-09-04 | — | — | US | claimed |
| US-20070191416-A1 | Tetrahydropyridoindole derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2007-08-16 | — | — | US | claimed |
| EP-1725553-A1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-11-29 | — | — | EP | claimed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | claimed |
| US-5721210-A | OLIGOPEPTIDES AS ANTIINFLAMMATORY AGENTS OR INTEGRIN RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 1998-02-24 | — | — | US | claimed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | claimed |
| EP-0650476-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-05-03 | — | — | EP | claimed |
| WO-1994022826-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-13 | — | — | WO | claimed |
| EP-0538399-A4 | — | — | 1994-05-04 | — | — | EP | claimed |
| EP-0538399-A1 | CYCLIC CELL ADHESION MODULATION COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 1993-04-28 | — | — | EP | claimed |
| WO-1992000995-A1 | CYCLIC CELL ADHESION MODULATION COMPOUNDS | TANABE SEIYAKU CO. LTD. (JP) | 1992-01-23 | — | — | WO | claimed |
| US-4461906-A | IMPROVING INTELLECTUAL CAPACITY | HOFFMANN-LA ROCHE INC. (US) | 1984-07-24 | — | — | US | claimed |
| US-4452807-A | CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1984-06-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221487-A1 | POLYETHLENE GLYCOL MODIFICATIONS OF THYMOSIN ALPHA-1 | CD4, TMSB10, ALG1 | PNMT 2131/4885NPC1 2599/4885RAB9A 554/4885 |
| US-20100234396-A1 | Tetrhydropyridoindole Derivatives | TPH2, TPH1, HTR5A | PNMT 53/4885NPC1 1928/4885RAB9A 1666/4885 |
| US-20070191416-A1 | Tetrahydropyridoindole derivatives | TPH2, TPH1, HTR2C | PNMT 17/4885NPC1 1701/4885RAB9A 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.